Effects of tenidap on canine experimental osteoarthritis i. morphologic and metalloprotease analysis

Arthritis & Rheumatism

Volumn 38, Issue 9, 1995, Pages 1290-1303

  Fernandes, Julio C ^a   Martel‐Pelletier, Johanne ^a   Otterness, Ivan G ^b   Lopez‐Anaya, Arturo ^b   Mineau, François ^a   Tardif, Ginette ^a   Pelletier, Jean‐Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; DICLOFENAC; MESSENGER RNA; OMEPRAZOLE; STROMELYSIN; TENIDAP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MECHANISM; DRUG MIXTURE; ENZYME ACTIVITY; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; OSTEOPHYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARTILAGE; COLLAGENASES; COMPARATIVE STUDY; DICLOFENAC; DOGS; DRUG THERAPY, COMBINATION; FEMUR; INDOLES; METALLOENDOPEPTIDASES; OMEPRAZOLE; OSTEOARTHRITIS; STROMELYSIN 1; SUPPORT, NON-U.S. GOV'T; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 0029097619     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780380918     Document Type: Article

References (64)

1. Canine anterior cruciate ligament transection model of osteoarthritis
2. Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fifty‐four months after transection of the anterior cruciate ligament
3. Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis
4. Proteinase‐mediated cartilage degradation in osteoarthritis
5. Coordinate synthesis of stromelysin, interleukin‐1 and oncogene proteins in experimental osteoarthritis: an immunohistochemical study
6. Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond‐Nuki dog model of osteoarthritis
7. Excess of metalloproteases over TIMP may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis
8. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis
9. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage
10. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage
11. Elevated synovial fluid levels of interleukin‐6 and tumor necrosis factor associated with early experimental canine osteoarthritis
12. Intraarticular injections with methylprednisolone acetate reduce osteoarthritic lesions in parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis
13. Protective effects of corticosteroids on cartilage lesions and osteophyte formation in the Pond‐Nuki dog model of osteoarthritis
14. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline
15. Tenidap: A new drug for arthritis
16. CP‐66,248, a new anti‐inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leucocytes in vitro
17. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen
18. Effect of tenidap on cartilage integrity in vitro
19. Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase
20. Clinical efficacy of CP‐66, 248 [5‐chloro‐2,3‐dihydro‐2‐oxo‐3‐(2‐thienylcarbonyl)‐indole‐1‐carboxamide in osteoarthritis (abstract)
21. Regulation of human normal and osteoarthritic chondrocyte interleukin‐1 receptor by antirheumatic drugs
22. A new model of osteoarthritis in rabbits. II. Evaluation of anti‐osteoarthritic effects of selected antirheumatic drugs administered systemically
23. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical and metabolic data
24. 3H) acetylated collagen
25. Assaying proteinases with azocoll
26. Extraction and isolation of mRNA from adult articular cartilage
27. Evidence for two functional gal promoters in intact Escherichia Coli cells
28. Human fibroblast collagenase: complete primary structure and homology to an oncogene transformation induced rat protein
29. Isolation and characterization of rat and human glyceraldehyde‐3‐phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene
30. Single dose pharmacokinetics of tenidap sodium in osteoarthritis (abstract)
31. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
32. The pharmacokinetics of diclofenac sodium following intravenous and oral administration
33. Comparative pharmacokinetic analysis of a novel sustained‐release dosage form of diclofenac sodium in healthy subjects
34. In vivo protective effects of prophylactic treatment with tiaprofenic acid or intra‐articular corticosteroids on osteoarthritic lesions in the experimental dog model
35. In vivo effects of naproxen on composition proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilage
36. In vivo effect of aspirin on canine osteoarthritic cartilage
37. A double‐blind randomised comparison of tenidap versus auranofin plus diclofenac in early rheumatoid arthritis (abstract)
38. Reduction of acute‐phase proteins with tenidap sodium, a cytokine‐modulating antirheumatic drug
39. Rheumatoid arthritis treated with tenidap and piroxicam: clinical associations with cytokine modulation by tenidap
40. Cytokine reduction in joint conditions
41. Cytokines and inflammation in cartilage degradation
42. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis: in vivo effects of antirheumatic drugs
43. Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis
44. Correlation of synovial fluid interleukin 6 (IL‐6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis
45. A possible systemic component of osteoarthritis: Elevated concentrations (by ELISA) of C‐reactive protein in serum of OA patients and modulation by tenidap (abstract)
46. Transforming growth factor‐ß1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint
47. Tenidap vs. naproxen vs. placebo in rheumatoid arthritis: a 2‐week study in patients with knee effusions (abstract)
48. Preliminary observations of chondral abrasion in a canine model
49. Biomechanical and biochemical properties of dog cartilage in experimentally induced osteoarthritis
50. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic cartilages and in explants of bovine articular cartilage cultured with interleukin 1
51. Degradation of proteoglycan aggregate by a cartilage metalloproteinase: evidence for the involvement of stromelysin in the generation of link protein heterogeneity in situ
52. Degradation of type IX collagen by matrix metalloproteinase 3 (stromelysin) from human rheumatoid synovial cells
53. Stromelysin is an activator of procollagenase: a study with natural and recombinant enzymes
54. Prostromelysin and procollagenase genes are differentially upregulated in chondrocytes from the knees of rabbits with experimental osteoarthritis
55. Differential in vivo expression of collagenase messenger RNA in synovium and cartilage: quantitative comparison with stromelysin messenger RNA levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis
56. Preferential mRNA expression of prostomelysin relative to procollagenase and in situ localization in human articular cartilage
57. Expression of c‐fos, jun‐B, metallothionein and metalloproteinase genes in human chondrocyte
58. Inhibition of interleukin 1 synthesis by tenidap: a new drug for arthritis
59. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage